These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 2013243)

  • 1. Antimicrobial activity of intravenous quinolones on the intestinal microflora in dogs.
    Thadepalli H; Chuah SK; Thadepalli CD; Mandal AK
    Chemotherapy; 1991; 37(1):6-14. PubMed ID: 2013243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of rufloxacin and norfloxacin effects on faecal flora.
    Marco F; Giménez MJ; Jiménez de Anta MT; Marcos MA; Salvá P; Aguilar L
    J Antimicrob Chemother; 1995 Jun; 35(6):895-901. PubMed ID: 7559202
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bactericidal activity of sparfloxacin and ciprofloxacin under anaerobic conditions.
    Cooper MA; Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Sep; 28(3):399-405. PubMed ID: 1660046
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydrophobicity and serum sensitivity of Klebsiella pneumoniae treated with sub-MICs of quinolones.
    Hostacká A
    Microbios; 1997; 91(368-369):137-43. PubMed ID: 9523422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative effects of the immediate and the extended release formulations of ciprofloxacin on normal human intestinal microflora.
    Rashid M; Weintraub A; Nord CE
    J Chemother; 2011 Jun; 23(3):145-9. PubMed ID: 21742583
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility pattern of bacterial isolates to lomefloxacin.
    Lalitha MK; Nisha AK; Bhattacharya SS; Ramamoorthy U; Lal HM
    Indian J Med Res; 1990 May; 91():182-4. PubMed ID: 2397938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of rufloxacin and ciprofloxacin on the intestinal microflora in a germ-free mice model.
    Gismondo MR; Drago L; Lombardi A; Fassina C; Cesana M
    Chemotherapy; 1995; 41(4):281-8. PubMed ID: 7555209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of low levels of ciprofloxacin on a chemostat model of the human colonic microflora.
    Carman RJ; Woodburn MA
    Regul Toxicol Pharmacol; 2001 Jun; 33(3):276-84. PubMed ID: 11407931
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of intravenously administered ciprofloxacin on aerobic intestinal microflora and fecal drug levels when administered simultaneously with sucralfate.
    Krueger WA; Ruckdeschel G; Unertl K
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1725-30. PubMed ID: 9257749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Postantibiotic effect of CI-960, enoxacin and ciprofloxacin on Escherichia coli: effect on morphology and haemolysin activity.
    Guan L; Burnham JC
    J Antimicrob Chemother; 1992 May; 29(5):529-38. PubMed ID: 1320604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overview of the fluoroquinolone antibiotics.
    Just PM
    Pharmacotherapy; 1993; 13(2 Pt 2):4S-17S. PubMed ID: 8386356
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin at low levels disrupts colonization resistance of human fecal microflora growing in chemostats.
    Carman RJ; Simon MA; Fernández H; Miller MA; Bartholomew MJ
    Regul Toxicol Pharmacol; 2004 Dec; 40(3):319-26. PubMed ID: 15546686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity of enoxacin versus ciprofloxacin, fleroxacin, lomefloxacin, ofloxacin, pefloxacin, and rufloxacin against uropathogens.
    Naber KG; Well M; Hollauer K; Kirchbauer D; Witte W
    Chemotherapy; 1998; 44(2):77-84. PubMed ID: 9551236
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro susceptibility of selected veterinary bacterial pathogens to ciprofloxacin, enrofloxacin and norfloxacin.
    Prescott JF; Yielding KM
    Can J Vet Res; 1990 Jan; 54(1):195-7. PubMed ID: 2306672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Frequency and expression of mutational resistance to the 4-quinolone antibacterials.
    Smith JT
    Scand J Infect Dis Suppl; 1986; 49():115-23. PubMed ID: 3547618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. gyrA mutations associated with quinolone resistance in Bacteroides fragilis group strains.
    Oh H; El Amin N; Davies T; Appelbaum PC; Edlund C
    Antimicrob Agents Chemother; 2001 Jul; 45(7):1977-81. PubMed ID: 11408211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation of in vitro activities of the fluoroquinolones to their in vivo efficacies.
    Fernandes PB; Swanson RN
    Drugs Exp Clin Res; 1988; 14(6):375-8. PubMed ID: 3145851
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of new quinolones on normal immune capabilities.
    Tawfik AF; Shoeb HA; Bishop SJ; al-Shammary FJ; Shibl AM
    J Chemother; 1990 Oct; 2(5):300-5. PubMed ID: 2090768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 4-quinolones inhibit biotransformation of caffeine.
    Harder S; Staib AH; Beer C; Papenburg A; Stille W; Shah PM
    Eur J Clin Pharmacol; 1988; 35(6):651-6. PubMed ID: 2853056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibacterial activity of fluoroquinolones in combination with zidovudine.
    Lewin CS; Allen RA; Amyes SG
    J Med Microbiol; 1990 Oct; 33(2):127-31. PubMed ID: 2121991
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.